| 1118 |
Preventive Treatment for Contacts of DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1230 |
State Programmatic Management of Drug-resistant TB [PMDT] Committee |
02/06/2024 |
DR-TB and PMDT |
| 1233 |
Cascade of Care for DR-TB Patients in the Private Sector |
02/06/2024 |
DR-TB and PMDT |
| 1234 |
Longer Oral M/XDR-TB: Regimen and Duration |
02/06/2024 |
DR-TB and PMDT |
| 1760 |
Diagnosis of DR-TB in Children |
02/06/2024 |
DR-TB and PMDT |
| 1771 |
Classification of Adverse Drug Events |
02/06/2024 |
DR-TB and PMDT |
| 1783 |
Palliative Care approach and benefits in DR-TB |
02/06/2024 |
DR-TB and PMDT |
| 1793 |
Screening among Household Contacts of DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1799 |
Clinical Diagnosis of Drug Resistance/ Probable DR-TB in Children |
02/06/2024 |
DR-TB and PMDT |
| 1801 |
Laboratory Diagnosis of Drug-resistant TB |
02/06/2024 |
DR-TB and PMDT |
| 1804 |
Treatment Algorithm for MDR/RR-TB |
02/06/2024 |
DR-TB and PMDT |
| 1805 |
Preparation of Patient-wise Boxes [PWB] for DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1806 |
Distribution of Second-line Drugs from the District Drug Store to the TB Unit Store |
02/06/2024 |
DR-TB and PMDT |
| 1807 |
H Mono/Poly DR-TB Patient Flow from Diagnosis to Treatment Initiation |
02/06/2024 |
DR-TB and PMDT |
| 1808 |
Additional Monitoring During Pregnancy and Lactation in Women on Shorter/Longer Oral MDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1815 |
Management of Hepato-toxicity During Treatment with Shorter/Longer Oral MDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1820 |
History of Programmatic Management of Drug Resistant TB (PMDT) in India |
02/06/2024 |
DR-TB and PMDT |
| 1822 |
DR-TB Services and Functions of Stakeholders |
02/06/2024 |
DR-TB and PMDT |
| 1847 |
Nodal DR-TB Centre |
02/06/2024 |
DR-TB and PMDT |
| 1849 |
Nodal DR-TB Centre Committee |
02/06/2024 |
DR-TB and PMDT |
| 1855 |
NTEP Services for Private Notified DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1856 |
Inclusion and Exclusion Criteria for the Use of Bedaquiline |
02/06/2024 |
DR-TB and PMDT |
| 1857 |
Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Drug Dose Administration |
02/06/2024 |
DR-TB and PMDT |
| 1858 |
Key Considerations for the Use of Bedaquiline [Bdq] |
02/06/2024 |
DR-TB and PMDT |
| 1859 |
Follow-up Monitoring of DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1860 |
Follow-up Evaluation of Patients on Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1861 |
Principles for Management of MDR/RR-TB in Children |
02/06/2024 |
DR-TB and PMDT |
| 1862 |
DR-TB Treatment in Pregnancy: Recommendation for the Use of Contraception |
02/06/2024 |
DR-TB and PMDT |
| 1863 |
Role of Surgery in DR-TB Treatment |
02/06/2024 |
DR-TB and PMDT |
| 1864 |
Use of M/XDR-TB Regimen in Patients with Seizure Disorders |
02/06/2024 |
DR-TB and PMDT |
